MATINAS BIOPHARMA HOLDINGS, INC.

(MTNB)
  Report
Delayed Nyse  -  05/16 04:00:00 pm EDT
0.6600 USD   -1.58%
05/12TRANSCRIPT : Matinas BioPharma Holdings, Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12MATINAS BIOPHARMA HOLDINGS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05/12Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highlights
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on redefining the intracellular delivery of nucleic acids and small molecules through its lipid nanocrystal (LNC) drug delivery platform. The Company is engaged in developing LYPDISO, as well as its LNC platform delivery technology and a pipeline of associated product candidates, including MAT2203 and MAT2501. Its LNC platform is designed to deliver a range of medicines, including small molecules, drugs with blood level-limiting toxicities, nucleic acid polymers, proteins, peptides, vaccines, and gene editing technologies. LYPDISO is a prescription-only omega-3 fatty acid-based composition, comprised primarily of eicosapentanoic acid (EPA) and docosapentanoic acid (DPA), intended for the treatment of cardiovascular and metabolic conditions. MAT2203 is an oral and non-toxic encochleated form of amphotericin B (CAmB). MAT2501 is an LNC formulation of the gram-negative antibiotic agent amikacin.

Number of employees : 31 people.
Sales per Business
20202021Delta
Novel Pharmaceutical Products0.16100%0.03100% -78.95%
USD in Million
Sales per region
20202021Delta
United States0.16100%0.03100% -78.95%
USD in Million
Managers
Name Title Age Since
Jerome D. Jabbour President, Chief Executive Officer & Director 47 2018
Keith A. Kucinski Chief Financial Officer 51 2019
Raphael J. Mannino, Dr. Chief Scientific Officer & Senior Vice President 74 2015
James J. Ferguson, Dr. Chief Medical Officer 67 2019
Hui Liu, Dr. Chief Technology Officer 54 2020
Thomas J. Hoover Chief Business Officer 52 2021
Theresa Matkovits, Dr. Chief Development Officer 53 2018
Members of the board
Name Title Age Since
Herbert J. Conrad Chairman 88 2013
James S. Scibetta Independent Director 56 2013
Eric J. Ende, Dr. Independent Director 52 2017
Matthew A. Wikler, Dr. Independent Director 71 2018
Natasha Giordano Independent Director 61 2020
Jerome D. Jabbour President, Chief Executive Officer & Director 47 2018
Kathryn Penkus Corzo Director - 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 216,864,526 210,530,614 97.1% 0 0.0% 97.1%
Shareholders
NameEquities%
The Vanguard Group, Inc. 7,834,876 3.61%
Vivo Capital LLC 6,451,612 2.97%
Herbert J. Conrad 4,694,566 2.16%
Sargent Investment Group LLC 3,643,979 1.68%
Anson Funds Management LP 3,583,996 1.65%
BlackRock Fund Advisors 2,448,811 1.13%
Baker Bros. Advisors LP 2,096,375 0.97%
Wellington Management Co. LLP 1,996,923 0.92%
Raphael J. Mannino 1,919,715 0.89%
Courage Capital Management LLC 1,900,000 0.88%
Company contact information
Matinas BioPharma Holdings, Inc.
1545 Route 206 South
Suite 302
Bedminster, NJ 07921-9999

Phone : +1.908.484.8805
Web : http://www.matinasbiopharma.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Matinas BioPharma Holdings, Inc.